South Dakota Investment Council Grows Stake in Zoetis Inc. $ZTS

Posted by George Bondi on Jul 30th, 2026

South Dakota Investment Council lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 77.2% during the 1st quarter, Holdings Channel.com reports. The fund owned 220,819 shares of the company’s stock after buying an additional 96,234 shares during the period. South Dakota Investment Council’s holdings in Zoetis were worth $26,103,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. J. Stern & Co. LLP boosted its holdings in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. Norges Bank acquired a new stake in Zoetis during the fourth quarter worth approximately $734,425,000. Vanguard Group Inc. raised its holdings in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new stake in shares of Zoetis during the 1st quarter worth approximately $286,660,000. Finally, Van ECK Associates Corp lifted its position in shares of Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after buying an additional 1,740,113 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of several research analyst reports. Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. UBS Group reduced their price target on shares of Zoetis from $99.00 to $85.00 and set a “neutral” rating for the company in a research report on Monday. Morgan Stanley reduced their price target on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Stifel Nicolaus decreased their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Finally, Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $118.33.

Check Out Our Latest Stock Analysis on ZTS

Zoetis Stock Performance

Shares of ZTS opened at $77.89 on Thursday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a market cap of $32.66 billion, a PE ratio of 12.92, a price-to-earnings-growth ratio of 1.21 and a beta of 0.75. The company’s 50 day simple moving average is $77.21 and its 200-day simple moving average is $103.02. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s payout ratio is currently 35.16%.

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.